JP6055845B2 - ペプチドおよびその使用 - Google Patents

ペプチドおよびその使用 Download PDF

Info

Publication number
JP6055845B2
JP6055845B2 JP2014551680A JP2014551680A JP6055845B2 JP 6055845 B2 JP6055845 B2 JP 6055845B2 JP 2014551680 A JP2014551680 A JP 2014551680A JP 2014551680 A JP2014551680 A JP 2014551680A JP 6055845 B2 JP6055845 B2 JP 6055845B2
Authority
JP
Japan
Prior art keywords
cell
peptide
cells
adiponectin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014551680A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509095A (ja
Inventor
ジョージ エドワード レインジャー、
ジョージ エドワード レインジャー、
パース ナレンドラン、
パース ナレンドラン、
ヘレン マクゲトリック、
ヘレン マクゲトリック、
ミリアム チメン、
ミリアム チメン、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Birmingham
Original Assignee
University of Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Birmingham filed Critical University of Birmingham
Publication of JP2015509095A publication Critical patent/JP2015509095A/ja
Application granted granted Critical
Publication of JP6055845B2 publication Critical patent/JP6055845B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
JP2014551680A 2012-01-13 2013-01-14 ペプチドおよびその使用 Active JP6055845B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201200555A GB201200555D0 (en) 2012-01-13 2012-01-13 Peptide
GB1200555.9 2012-01-13
PCT/GB2013/050068 WO2013104928A1 (en) 2012-01-13 2013-01-14 Peptide and uses thereof

Publications (2)

Publication Number Publication Date
JP2015509095A JP2015509095A (ja) 2015-03-26
JP6055845B2 true JP6055845B2 (ja) 2016-12-27

Family

ID=45813974

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014551680A Active JP6055845B2 (ja) 2012-01-13 2013-01-14 ペプチドおよびその使用

Country Status (7)

Country Link
US (1) US9597368B2 (enExample)
EP (1) EP2802342B1 (enExample)
JP (1) JP6055845B2 (enExample)
CN (1) CN104168910B (enExample)
GB (1) GB201200555D0 (enExample)
IN (1) IN2014DN05784A (enExample)
WO (1) WO2013104928A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110381920A (zh) * 2017-03-09 2019-10-25 雅利斯塔制药公司 用于干眼病的肽
US12226449B2 (en) * 2018-11-15 2025-02-18 The University Of Toledo Materials and methods for the prevention of rheumatoid arthritis
US20210100870A1 (en) * 2019-10-08 2021-04-08 The University Of Birmingham Bone disease treatment
GB202211043D0 (en) 2022-07-28 2022-09-14 Univ Birmingham Peptide agonist
CN117244043B (zh) * 2023-11-02 2024-09-20 徐州医科大学附属医院 破伤风类毒素在治疗血管内皮细胞损伤中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1405072A2 (en) 2000-12-29 2004-04-07 Oxford GlycoSciences (UK) Limited Proteins, genes and their use for diagnosis and treatment of kidney response
JP2010520236A (ja) * 2007-02-28 2010-06-10 ユニバーシティ オブ バージニア パテント ファンデーション リソフィリンアナログとその使用法
KR20180102215A (ko) * 2007-11-27 2018-09-14 더 유니버시티 오브 브리티쉬 콜롬비아 관절염의 진단과 치료를 위한 14-3-3 에타 항체 및 이의 용도
CA2739076A1 (en) * 2008-10-02 2010-04-08 Celtaxsys, Inc. Methods of modulating the negative chemotaxis of immune cells
CA2780759A1 (en) * 2009-12-01 2011-06-09 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
WO2011154496A1 (en) 2010-06-09 2011-12-15 Poxel Treatment of type 1 diabetes

Also Published As

Publication number Publication date
JP2015509095A (ja) 2015-03-26
EP2802342B1 (en) 2018-05-02
WO2013104928A1 (en) 2013-07-18
CN104168910B (zh) 2017-07-28
EP2802342A1 (en) 2014-11-19
US9597368B2 (en) 2017-03-21
GB201200555D0 (en) 2012-02-29
CN104168910A (zh) 2014-11-26
IN2014DN05784A (enExample) 2015-05-15
US20150051137A1 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
KR102442984B1 (ko) 글루카곤 수용체 길항 항체를 이용한 제 1 형 당뇨병의 치료 방법
JP2008504249A (ja) 糖尿病を治療するための方法
JP6055845B2 (ja) ペプチドおよびその使用
CN102389413A (zh) 用于治疗糖尿病的组合物及其应用
JP2015514778A (ja) 糖尿病を処置する方法および／または移植後の膵島の生存を促進する方法
ES2908838T3 (es) Antagonista del receptor de GLP-1 para usar en el tratamiento del hiperinsulinismo congénito
JP2024178420A (ja) 多発性硬化症を治療するためのｌｏｕ０６４
US20190002527A1 (en) Methods and compositions for the inhibition of trpv4
US9839671B2 (en) Peptide and uses therefor
US20190062441A1 (en) Methods For Treating Rare Genetic Disorders Using Glucagon Receptor Antagonistic Antibodies
JP2017517561A (ja) 最適化ハムスターｒｅｇ３ガンマペプチドを利用する糖尿病を有する患者の間でのインスリン非依存性
US8927498B2 (en) Compositions and methods useful in enhancement of memory
CN120676946A (zh) Debio-0123与替莫唑胺和放射治疗组合用于治疗胶质瘤
JP2019520341A (ja) 代謝疾患を治療する組成物と方法
US20140044726A1 (en) Preparations and methods for treating malignancies
Han et al. Pulmonary Delivery of Engineered Exosomes to Suppress Postoperative Melanoma Lung Metastasis through Preventing Premetastatic Niche Formation
EP2578227B1 (en) Cancer therapy method
EP4665346A1 (en) Debio-0123 in combination with temozolomide and radiotherapy for use in treating glioma
US20210087582A1 (en) Method and composition for endogenous production of constitutively activated receptors, and receptors with broader binding ranges or higher affinity than native receptors
WO2024019976A1 (en) Methods for treating cancer including glatiramer acetate and immune checkpoint inhibitors
CN101711862B (zh) 一种炎症性疾病相关的药物靶点及其应用
US20100284911A1 (en) Preparations and methods for treating malignancies

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160907

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161205

R150 Certificate of patent or registration of utility model

Ref document number: 6055845

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250